RxDoctor Payments Data

Matthew Zipse, MD

Interventional Cardiology · Aurora, CONPI 1861652794

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $91,956 of the $137,462 with a category attached, or 66.9%. 9 manufacturers reported payments, led by Philips North America LLC at 40.7% of the total. Among interventional cardiology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$137,462in general payments, 2019–2025

Across 274 payments — averaging $501.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$56K
  • Medical Device Business Services, Inc.$34K
  • Boston Scientific$16K
  • Biosense Webster, Inc.$16K
  • Abbott$8K
  • Medtronic$7K
  • plus $667 from 3 others

What the payments were for

  • Consulting fees$91,95667%
  • Speaking & faculty fees$21,08815%
  • Travel & lodging$15,97512%
  • Food & beverage$8,4436%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,462 in reported general payments places this provider in the 90th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$162,474
Medicare patients
1,103
Services billed
2,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$59,175
Flecainide Acetate23$1,087
Metoprolol Succinate41$652
Doxycycline Hyclate12$56

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →